Nifty
:
24973.10
Sensex
:
81425.15
104.50 (0.42%)
323.83 (0.40%)
Nifty
Sensex
:
:
24973.10
81425.15
104.50 (0.42%)
323.83 (0.40%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
65/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
2130.90
10-Sep-2025
  • Open
  • High
  • Low
  • Previous Close
  •  2112
  •  2135
  •  2104
  •  2116.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  773741
  •  1645001599.2
  •  2284.8
  •  1275.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 60,146.87
  • 79.24
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 60,635.84
  • 0.12%
  • 6.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.29%
  • 11.68%
  • FII
  • DII
  • Others
  • 20.62%
  • 16.05%
  • 2.71%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.83
  • 4.01
  • 4.77

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.05
  • 2.44
  • 7.54

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.49
  • 1.54
  • 10.03

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.30
  • 13.69
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.73
  • 2.81
  • 3.43

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.81
  • 11.33
  • 13.59

Earnings Forecasts:

(Updated: 08-09-2025)
Description
2024
2025
2026
2027
Adj EPS
37.11
61.83
78.93
97.32
P/E Ratio
57.03
34.23
26.81
21.75
Revenue
13145.8
14873.9
16670.9
18480
EBITDA
2289.2
2837.12
3430.83
3952.28
Net Income
1047.1
1745.64
2227.83
2629.3
ROA
6.89
13.49
16.03
P/B Ratio
6.75
5.67
4.77
3.98
ROE
12.54
17.68
18.24
17.72
FCFF
-1725.82
1102.69
1548.86
1384.29
FCFF Yield
-2.74
1.75
2.46
2.2
Net Debt
767.44
-1529.28
-2664.4
-1443.9
BVPS
313.59
373.23
443.86
532.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
3,264.44
3,244.19
0.62%
3,256.21
3,062.95
6.31%
3,387.55
2,506.70
35.14%
3,433.80
3,207.38
7.06%
Expenses
2,683.92
2,655.97
1.05%
2,695.18
2,558.61
5.34%
2,787.32
2,715.35
2.65%
2,831.88
2,745.09
3.16%
EBITDA
580.52
588.21
-1.31%
561.03
504.34
11.24%
600.23
-208.65
-
601.91
462.28
30.20%
EBIDTM
17.78%
18.13%
17.23%
16.47%
17.72%
-8.32%
17.53%
14.41%
Other Income
26.44
31.49
-16.04%
11.68
773.16
-98.49%
31.13
45.41
-31.45%
39.42
1.70
2,218.82%
Interest
58.23
39.58
47.12%
66.71
148.56
-55.10%
52.29
134.34
-61.08%
48.48
121.46
-60.09%
Depreciation
129.93
117.79
10.31%
125.20
151.34
-17.27%
122.74
147.07
-16.54%
120.28
141.45
-14.97%
PBT
95.58
462.33
-79.33%
7.97
530.83
-98.50%
456.33
-521.38
-
472.57
-124.35
-
Tax
48.61
122.10
-60.19%
3.59
1,769.47
-99.80%
108.30
-71.80
-
118.09
55.95
111.06%
PAT
46.97
340.24
-86.20%
4.38
-1,238.65
-
348.03
-449.58
-
354.49
-180.30
-
PATM
1.44%
10.49%
0.13%
-40.44%
10.27%
-17.94%
10.32%
-5.62%
EPS
1.66
12.06
-86.24%
0.16
-43.17
-
12.33
-12.45
-
12.55
-2.90
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
13,342.00
13,321.74
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
Net Sales Growth
10.99%
12.77%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
 
Cost Of Goods Sold
4,258.84
4,287.37
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
Gross Profit
9,083.16
9,034.37
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
GP Margin
68.08%
67.82%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
Total Expenditure
10,998.30
10,970.36
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
Power & Fuel Cost
-
131.40
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
120.47
% Of Sales
-
0.99%
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
Employee Cost
-
3,022.06
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
% Of Sales
-
22.69%
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
Manufacturing Exp.
-
987.39
1,012.86
633.51
784.63
638.74
669.50
725.16
648.59
546.75
956.59
% Of Sales
-
7.41%
8.57%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
General & Admin Exp.
-
1,457.32
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
% Of Sales
-
10.94%
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
Selling & Distn. Exp.
-
1,051.00
892.72
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
% Of Sales
-
7.89%
7.56%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
Miscellaneous Exp.
-
33.81
54.46
48.49
78.68
121.44
47.19
33.29
314.55
88.52
892.67
% Of Sales
-
0.25%
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
EBITDA
2,343.69
2,351.38
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
EBITDA Margin
17.57%
17.65%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
Other Income
108.67
113.72
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
20.00
Interest
225.71
207.06
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
178.88
Depreciation
498.15
486.01
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
234.28
PBT
1,032.45
1,772.03
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
Tax
278.59
352.07
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
300.94
Tax Rate
26.98%
25.16%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
PAT
753.87
1,047.09
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
PAT before Minority Interest
753.70
1,047.14
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
Minority Interest
-0.17
-0.05
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
PAT Margin
5.65%
7.86%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
PAT Growth
149.33%
-
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
 
EPS
26.71
37.10
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29
26.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
8,849.44
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Total Reserves
8,812.16
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
Non-Current Liabilities
109.35
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
512.70
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,967.02
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
Trade Payables
2,579.53
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
Other Current Liabilities
1,081.54
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
Short Term Borrowings
1,681.49
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
Short Term Provisions
624.46
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
134.03
Total Liabilities
14,925.44
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
Net Block
4,486.82
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
Gross Block
10,364.92
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
Accumulated Depreciation
5,878.10
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
Non Current Assets
5,629.98
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
Capital Work in Progress
834.83
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
Non Current Investment
56.35
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
17.20
Long Term Loans & Adv.
242.74
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
69.99
Other Non Current Assets
9.23
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
Current Assets
9,295.47
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
3,028.53
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
Sundry Debtors
3,341.95
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
Cash & Bank
1,705.23
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
Other Current Assets
1,219.76
178.21
316.61
297.46
1,371.54
1,147.78
1,312.40
1,391.61
1,273.61
986.77
Short Term Loans & Adv.
1,074.79
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
594.89
Net Current Assets
3,328.44
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
Total Assets
14,925.45
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
-827.60
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
PBT
1,399.21
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
Adjustment
982.01
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
Changes in Working Capital
-2,528.69
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
Cash after chg. in Working capital
-147.47
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-680.13
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
2.09
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
Net Fixed Assets
-307.30
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
Net Investments
-2,230.12
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
Others
2,539.51
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
Cash from Financing Activity
787.04
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
Net Cash Inflow / Outflow
-38.46
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
Opening Cash & Equivalents
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
Closing Cash & Equivalent
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
313.28
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
ROA
7.42%
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
ROE
12.56%
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
ROCE
16.16%
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
Fixed Asset Turnover
2.94
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
1.96
Receivable days
32.34
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
119.39
Inventory Days
34.46
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
67.68
Payable days
217.75
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
117.03
Cash Conversion Cycle
-150.94
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
Total Debt/Equity
0.25
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
Interest Cover
7.76
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28
6.84

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Glenmark Pharmaceuticals initiates multi-country Phase 3 Clinical Trial for Envafolimab
    5th Sep 2025, 12:41 PM

    The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrolment and dosing in the country

    Read More
  • Glenmark Pharmaceuticals’ arm to launch Eribulin Mesylate Injection
    2nd Sep 2025, 12:28 PM

    The company will begin distribution in September 2025

    Read More
  • Glenmark Pharma makes remaining investment of Rs 0.24 crore in O2 Renewable Energy XXIV
    21st Aug 2025, 11:08 AM

    Pursuant to this, the company now holds 32.95% stake in O2 Renewable Energy XXIV

    Read More
  • Glenmark Pharmaceuticals’ arm to launch Micafungin for Injection
    19th Aug 2025, 12:22 PM

    The company will begin distribution in September 2025

    Read More
  • Glenmark Pharmaceuticals reports 86% drop in Q1 consolidated net profit
    16th Aug 2025, 16:05 PM

    The total consolidated income of the company increased by 0.46% at Rs 3290.88 crore for Q1FY26

    Read More
  • Glenmark Pharma - Quarterly Results
    14th Aug 2025, 17:14 PM

    Read More
  • Glenmark Pharmaceuticals gets warning letter for Indore facility
    14th Jul 2025, 10:23 AM

    The U.S. FDA had inspected the Glenmark’s Indore site from February 03, 2025 to February 14, 2025

    Read More
  • Glenmark Pharmaceuticals’ arm enters into licensing agreement with AbbVie
    11th Jul 2025, 12:21 PM

    AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China

    Read More
  • Glenmark Pharmaceuticals launches TEVIMBRA in India
    24th Jun 2025, 12:30 PM

    This launch marks Glenmark’s first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio

    Read More
  • USFDA concludes GMP inspection at Glenmark Pharmaceuticals’ USA manufacturing facility
    18th Jun 2025, 10:37 AM

    At the end of the inspection, the Company was issued a Form 483 with five observations

    Read More
  • Glenmark Pharmaceuticals to launch zanubrutinib in India
    9th Jun 2025, 12:00 PM

    Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.